fda compounding glp-1 enforcement news november 2025 What Patients Need to Know About the Policy Changes Pharmaceutical supply chain issues in

Clinical Evidence of Blood Pressure Reduction The data from various clinical trials indicates that semaglutide can lower systolic blood pressure

New PBM Requirements Recent letters from PBMs illustrate how they are setting their own coverage criteria, which are often more restrictive than those set by the FDA

Your provider can help set expectations and determine whether treatment remains appropriate based on your medical history, symptoms, and follow-up review

The treatment was given for 48 weeks (in addition to their usual medication) and then the participants were followed for another 12-weeks without exenatide (or placebo) in a washout period

Ozempic GLP-1 Overview Ozempic contains semaglutide and is one of the most well-known GLP-1 medications

2